Atıf İçin Kopyala
Bekoz H., Karadurmus N., Paydas S., Turker A., Toptas T., Tuglular T. F., ...Daha Fazla
ANNALS OF ONCOLOGY, cilt.28, sa.10, ss.2496-2502, 2017 (SCI-Expanded)
-
Yayın Türü:
Makale / Tam Makale
-
Cilt numarası:
28
Sayı:
10
-
Basım Tarihi:
2017
-
Doi Numarası:
10.1093/annonc/mdx341
-
Dergi Adı:
ANNALS OF ONCOLOGY
-
Derginin Tarandığı İndeksler:
Science Citation Index Expanded (SCI-EXPANDED), Scopus
-
Sayfa Sayıları:
ss.2496-2502
-
Anahtar Kelimeler:
Hodgkin lymphoma, resistant/relapsed disease, programmed death 1 (PD-1) blocker, nivolumab, BRENTUXIMAB VEDOTIN, PD-1 BLOCKADE
-
Ankara Üniversitesi Adresli:
Evet
Özet
Background: Reed-Sternberg cells of classical Hodgkin's lymphoma (cHL) are characterized by genetic alterations at the 9p24.1 locus, leading to over-expression of programmed death-ligand 1 and 2. In a phase 1b study, nivolumab, a PD-1-blocking antibody, produced a high response in patients with relapsed or refractory cHL, with an acceptable safety profile.